文献速递类风湿关节炎

达标治疗类风湿关节炎与未分化关节炎的长期死亡率:BeSt与IMPROVED队列结果

Long-term mortality in treated-to-target RA and UA: results of the BeSt and IMPROVED cohort.
PubMed 文献 · Ann Rheum Dis · 2024-01-11

研究评估BeSt(508例早期RA)和IMPROVED(610例早期RA/UA)两个达标治疗队列的长期死亡率,随访至2021年12月31日。两个队列均存在超额死亡(BeSt SMR 1.32,95%CI 1.14-1.53;IMPROVED SMR 1.33,95%CI 1.10-1.63),10年后显现,ACPA阳性吸烟者SMR最高(BeSt 2.80,IMPROVED 2.14)。主要死因为恶性肿瘤。

要点

  • BeSt和IMPROVED两个达标治疗队列均存在超额死亡,SMR分别为1.32和1.33,均在治疗开始10年后显现。
  • ACPA阳性吸烟者超额死亡最显著,BeSt SMR 2.80(95%CI 2.16-3.64),IMPROVED SMR 2.14(95%CI 1.33-3.45)。
  • 主要死因为恶性肿瘤,试验期间平均DAS每升高1分,BeSt死亡HR 1.34(95%CI 0.96-1.86),IMPROVED HR 1.13(95%CI 0.67-1.91)。

核心结论

  • 达标治疗长期治疗后,RA患者在治疗开始10年后出现超额死亡,吸烟是重要危险因素。

研究设计与样本

  • BeSt研究(n=508,早期RA)于2000年至2012年进行,10年内以DAS≤2.4为达标目标治疗。
  • IMPROVED研究(n=610,早期RA/UA)于2007年至2015年进行,5年内以DAS<1.6为达标目标治疗。
  • 评估BeSt/IMPROVED参与者至2021年12月31日(含)的生存状态,计算标准化死亡比(SMR),并按ACPA和吸烟状态分层分析。

主要发现

  • BeSt队列SMR 1.32(95%CI 1.14-1.53),IMPROVED队列SMR 1.33(95%CI 1.10-1.63),超额死亡均在10年后显现。
  • ACPA阳性吸烟者超额死亡有统计学意义:BeSt SMR 2.80(95%CI 2.16-3.64),IMPROVED SMR 2.14(95%CI 1.33-3.45)。
  • BeSt平均生存时间较预期缩短10个月(95%CI 5-16),IMPROVED缩短13个月(95%CI 11-16)。
  • 试验期间平均DAS每升高1分,死亡HR为BeSt 1.34(95%CI 0.96-1.86),IMPROVED 1.13(95%CI 0.67-1.91)。
  • 主要死因为恶性肿瘤。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To study long-term (up to 20-year) mortality of two treat-to-target trial cohorts in undifferentiated arthritis (UA) and early rheumatoid arthritis (RA). METHODS: The BeSt (BehandelStrategieën) study (n=508, early RA) was performed between 2000 and 2012. For 10 years, patients were treated-to-target disease activity score (DAS)≤2.4.The Induction therapy with Methotrexate and Prednisone in Rheumatoid Or Very Early arthritic Disease (IMPROVED) study (n=610, early RA/UA) was performed between 2007 and 2015. For 5 years, patients were treated-to-target DAS<1.6.Vital status of BeSt/IMPROVED participants was assessed up to and including 31 December 2021. Standardised mortality ratios (SMRs) were calculated. Stratified analyses for anticitrullinated protein antibody (ACPA) and smoking status were performed. Death causes and the potential effect of disease activity during the trial period on late mortality were assessed. RESULTS: Excess mortality was found in both BeSt (SMR 1.32, 95% CI 1.14 to 1.53) and IMPROVED (SMR 1.33, 95% CI 1.10 to 1.63) and became manifest after 10 years. Excess mortality was statistically significant in ACPA+ patients who smoked (BeSt: SMR 2.80, 95% CI 2.16 to 3.64; IMPROVED: 2.14, 95% CI 1.33 to 3.45). Mean survival time was 10 (95% CI 5 to 16) months shorter than expected in BeSt and 13 (95% CI 11 to 16) months in IMPROVED. The HR for mortality was 1.34 (95% CI 0.96 to 1.86; BeSt)/1.13 (95% CI 0.67 to 1.91; IMPROVED) per 1 point increase in mean DAS during the trial. The main cause of death was malignancy. CONCLUSIONS: After long-term treatment-to-target, excess mortality occurred in patients with RA after>10 years since treatment start, with smoking as an important risk factor.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Heckert SL, Maassen JM, le Cessie S, et al. Long-term mortality in treated-to-target RA and UA: results of the BeSt and IMPROVED cohort. Ann Rheum Dis. 2024. PMID: 37979961. doi:10.1136/ard-2023-224814

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。